Your browser doesn't support javascript.
loading
Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation.
Badodi, Sara; Pomella, Nicola; Zhang, Xinyu; Rosser, Gabriel; Whittingham, John; Niklison-Chirou, Maria Victoria; Lim, Yau Mun; Brandner, Sebastian; Morrison, Gillian; Pollard, Steven M; Bennett, Christopher D; Clifford, Steven C; Peet, Andrew; Basson, M Albert; Marino, Silvia.
Afiliación
  • Badodi S; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Pomella N; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Zhang X; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Rosser G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Whittingham J; Centre for Craniofacial and Regenerative Biology, King's College London, London, UK.
  • Niklison-Chirou MV; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Lim YM; Centre for Therapeutic Innovation (CTI-Bath), Department of Pharmacy & Pharmacology, University of Bath, Bath, UK.
  • Brandner S; UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
  • Morrison G; UCL Queen Square Institute of Neurology and The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, UK.
  • Pollard SM; Centre for Regenerative Medicine & Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK.
  • Bennett CD; Centre for Regenerative Medicine & Cancer Research UK Edinburgh Centre, The University of Edinburgh, Edinburgh, UK.
  • Clifford SC; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Peet A; Birmingham Women and Children's Hospital, Birmingham, UK.
  • Basson MA; Newcastle University Centre for Cancer, Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle upon Tyne, UK.
  • Marino S; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Nat Commun ; 12(1): 2148, 2021 04 12.
Article en En | MEDLINE | ID: mdl-33846320
ABSTRACT
Deregulation of chromatin modifiers plays an essential role in the pathogenesis of medulloblastoma, the most common paediatric malignant brain tumour. Here, we identify a BMI1-dependent sensitivity to deregulation of inositol metabolism in a proportion of medulloblastoma. We demonstrate mTOR pathway activation and metabolic adaptation specifically in medulloblastoma of the molecular subgroup G4 characterised by a BMI1High;CHD7Low signature and show this can be counteracted by IP6 treatment. Finally, we demonstrate that IP6 synergises with cisplatin to enhance its cytotoxicity in vitro and extends survival in a pre-clinical BMI1High;CHD7Low xenograft model.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adaptación Fisiológica / Neoplasias Cerebelosas / Epigénesis Genética / Inositol / Meduloblastoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adaptación Fisiológica / Neoplasias Cerebelosas / Epigénesis Genética / Inositol / Meduloblastoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido